Relationship of Therapeutic Improvements and 28-Day Case Fatality in Patients Hospitalized With Acute Myocardial Infarction Between 1978 and 1993 in the REGICOR Study, Gerona, Spain
- 6 April 1999
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 99 (13) , 1767-1773
- https://doi.org/10.1161/01.cir.99.13.1767
Abstract
Background —The aim of this study was to analyze 28-day case fatality trends between 1978 and 1993 among hospitalized acute myocardial infarction (AMI) patients in the REGICOR registry, Gerona, Spain, and relate them to thrombolytic and antiplatelet drug use and changes in patient characteristics. Methods and Results —A total of 2053 consecutive patients 25 to 74 years of age with a first Q-wave AMI admitted to the reference hospital between 1978 and 1993 were registered. Clinical characteristics and patient management were recorded. Four 4-year periods were considered: 1978 to 1981, 1982 to 1985 (prethrombolytic therapy), 1986 to 1989 (thrombolytic and antiplatelet drugs introduced), and 1990 to 1993 (thrombolytic and antiplatelet drugs used routinely). The end point was death at 28 days. Case fatality at 28 days decreased 6% per year between 1978 and 1993. A logistic model adjusted for comorbidity and severity showed the last 3 periods to present a steep decrease in the OR of death at 28 days: 0.86 (95% CI, 0.52 to 1.41), 0.59 (95% CI, 0.35 to 0.99), and 0.40 (95% CI, 0.24 to 0.69), respectively, compared with the first period. After 1986, 85.7% of the 112 lives saved could be attributed to the use of antiplatelet and thrombolytic drugs. Adjusted relative risk reduction was 56.0% for antiplatelet drugs, 34.1% for thrombolytic drugs, and 77.9% for the 2 combined. Conclusions —Our results strongly suggest that new therapies introduced since 1986 have contributed to the decrease in 28-day case fatality of patients admitted with a first Q-wave AMI. This decrease could be attributable mainly to the use of antiplatelet and thrombolytic drugs. These findings should encourage the routine use of thrombolytic and antiplatelet drugs and particularly their combination in the acute phase of AMI.Keywords
This publication has 15 references indexed in Scilit:
- Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: A population-based comparisonJournal of the American College of Cardiology, 1996
- Recent Trends in Acute Coronary Heart Disease — Mortality, Morbidity, Medical Care, and Risk FactorsNew England Journal of Medicine, 1996
- Reduced in-hospital mortality from acute myocardial infarction with general adoption of thrombolytic treatment in the North West Thames health region 1979-1991.Heart, 1995
- Population-wide mortality trends among patients hospitalized for acute myocardial infarction: The Ontario experience, 1981 to 1991Journal of the American College of Cardiology, 1994
- Changes in risk factors explain changes in mortality from ischaemic heart disease in FinlandBMJ, 1994
- Trends in mortality from cardiovascular and cerebrovascular diseaseInternational Journal of Public Health, 1993
- Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysisJournal of the American College of Cardiology, 1991
- Aspirin and fibrinolysis in acute myocardial infarction: Meta-analytic evidence for synergyJournal of Clinical Epidemiology, 1991
- Improved prognosis since 1969 of myocardial infarction treated in a coronary care unit: lack of relation with changes in severity.BMJ, 1989
- Deaths in early phase of acute myocardial infarction and approaches for reducing the in-hospital and out-hospital case-fatality rates of the disease.Japanese Circulation Journal, 1987